Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

285
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
285
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

458
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
458
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

614
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
614
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

300
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
300
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

205
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
205
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

378
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
378

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Compliance with existing standards: overview comparing Cochrane with non-Cochrane living systematic reviews.

Systematic reviews·2026
Same author

Challenges in advising people with severe mental illness to quit smoking: A conversation analysis of patient resistance.

Patient education and counseling·2026
Same author

Scoping review of e-cigarette use in the perioperative setting: a protocol.

BMJ open·2026
Same author

Prevalence, Risk Factors, and Treatments for Suicidality in People Living with Premenstrual Dysphoric Disorder (PMDD): A Systematic Review.

Administration and policy in mental health·2026
Same author

Electronic cigarettes for smoking cessation: An overview of systematic reviews and evidence and gap map.

Addiction (Abingdon, England)·2026
Same author

Reduced-nicotine cigarettes for smoking cessation and reduction.

The Cochrane database of systematic reviews·2026

Related Experiment Video

Updated: Jul 29, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

111

Antidepressants for smoking cessation.

Anisa Hajizadeh1, Seth Howes1, Annika Theodoulou1

  • 1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

The Cochrane Database of Systematic Reviews
|May 25, 2023
PubMed
Summary

Bupropion effectively aids long-term smoking cessation, but may increase serious adverse events and treatment discontinuation. Nortriptyline also shows benefits, though bupropion may be more effective than placebo.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.7K
Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
06:39

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Published on: August 28, 2017

14.4K

Related Experiment Videos

Last Updated: Jul 29, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

111
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.7K
Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
06:39

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Published on: August 28, 2017

14.4K

Area of Science:

  • Pharmacology and Addiction Medicine
  • Clinical Trial Analysis
  • Public Health Interventions

Background:

  • Antidepressants have varied mechanisms, but may aid smoking cessation by alleviating nicotine withdrawal symptoms or impacting neural pathways of addiction.
  • Nicotine addiction is a significant public health concern, necessitating effective pharmacological interventions for cessation.

Purpose of the Study:

  • To evaluate the efficacy, safety, and tolerability of antidepressant medications for long-term tobacco smoking cessation.
  • To synthesize evidence from randomized controlled trials comparing antidepressants with placebo or other cessation aids.

Main Methods:

  • Systematic review and meta-analysis of 124 randomized controlled trials (48,832 participants) including adults and adolescents.
  • Primary outcome: smoking cessation at six months follow-up, using validated abstinence rates.
  • Secondary outcomes: harms, serious adverse events (SAEs), and treatment discontinuation.

Main Results:

  • High-certainty evidence shows bupropion increases smoking cessation rates compared to placebo (RR 1.60).
  • Bupropion is less effective than varenicline and combination nicotine replacement therapy (NRT), but comparable to single-form NRT.
  • Bupropion is associated with higher rates of serious adverse events (SAEs) and treatment discontinuation compared to placebo.

Conclusions:

  • Bupropion is an effective aid for long-term smoking cessation, supported by high-certainty evidence.
  • While effective, bupropion's use is tempered by potential increases in SAEs and treatment discontinuations.
  • Nortriptyline also demonstrates efficacy, but further research is needed on harms and tolerability for antidepressants in smoking cessation.